Exelixis, Inc. (NASDAQ:EXEL) announced positive overall survival (OS) results from METEOR, the phase 3 pivotal trial comparing cabozantinib to everolimus in 658 patients with …
Exelixis, Inc. (NASDAQ:EXEL) announced that the U.
Analyst John Sonnier of William Blair began his 2016 coverage this week by providing updates on two biotech stocks, Celgene Corporation (NASDAQ:CELG) and …
Exelixis, Inc. (NASDAQ:EXEL) announced that it has submitted a Marketing Authorization Application (MAA) for cabozantinib as a treatment for patients with advanced renal cell …
Exelixis, Inc. (NASDAQ:EXEL) announced that the European Commission (EC) has approved COTELLIC™ (cobimetinib) for use in combination with vemurafenib for the treatment of adult patients with unresectable …
Exelixis, Inc. (NASDAQ:EXEL) announced the company has initiated submission of its rolling New Drug Application (NDA) to the U.
Recently, various executives have taken part in insider selling activity for the stocks of Facebook Inc (NASDAQ:FB), Exelixis, Inc. (NASDAQ:EXEL), Neuralstem, Inc.
Exelixis, Inc. (NASDAQ:EXEL) announced positive overall survival (OS) results from coBRIM, the phase 3 pivotal trial evaluating cobimetinib, a specific MEK inhibitor discovered byExelixis, …
In a research report released today, Cowen analyst Eric Schmidt reiterated an Outperform rating on shares of Exelixis Inc. (NASDAQ:EXEL), following Friday’s news that …
